000278069 001__ 278069
000278069 005__ 20250504001224.0
000278069 0247_ $$2doi$$a10.1186/s13195-025-01742-6
000278069 0247_ $$2pmid$$apmid:40281595
000278069 0247_ $$2altmetric$$aaltmetric:176730072
000278069 037__ $$aDZNE-2025-00560
000278069 041__ $$aEnglish
000278069 082__ $$a610
000278069 1001_ $$0P:(DE-2719)9002356$$aFischer, Larissa$$b0$$eFirst author
000278069 245__ $$aDifferential effects of aging, Alzheimer's pathology, and APOE4 on longitudinal functional connectivity and episodic memory in older adults.
000278069 260__ $$aLondon$$bBioMed Central$$c2025
000278069 3367_ $$2DRIVER$$aarticle
000278069 3367_ $$2DataCite$$aOutput Types/Journal article
000278069 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1745829907_15614
000278069 3367_ $$2BibTeX$$aARTICLE
000278069 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000278069 3367_ $$00$$2EndNote$$aJournal Article
000278069 520__ $$aBoth aging and Alzheimer's disease (AD) affect brain networks, with early disruptions occurring in regions involved in episodic memory. Few studies have, however, focused on distinguishing region-specific effects of AD-biomarker negative 'normal' aging and early amyloid- and tau pathology on functional connectivity. Further, longitudinal studies combining imaging, biomarkers, and cognition are rare.We assessed resting-state functional connectivity (rsFC) strength and graph measures in the episodic memory network including the medial temporal lobe (MTL), posteromedial cortex (PMC), and medial prefrontal cortex alongside cognition over two years. For this preregistered study, we included 100 older adults who were amyloid- and tau-negative using CSF and PET measurements to investigate 'normal' aging, and 70 older adults who had longitudinal CSF data available to investigate functional changes related to early AD pathology. All participants were cognitively unimpaired older adults from the PREVENT-AD cohort. We used region of interest (ROI)-to-ROI bivariate correlations, graph analysis, and multiple regression models.In the amyloid- and tau-negative sample, rsFC strength within PMC, between parahippocampal cortex and inferomedial precuneus, and between posterior hippocampus and inferomedial precuneus decreased over time. Additionally, we observed a longitudinal decrease in global efficiency. Further, there was a steeper longitudinal decrease in rsFC and global efficiency with higher baseline age particularly of parahippocampal-gyrus regions. Further, lower rsFC strength within PMC was associated with poorer longitudinal episodic memory performance. In the sample with available CSF data, a steeper increase in rsFC between anterior hippocampus and superior precuneus was related to higher baseline AD pathology. Higher MTL-PMC rsFC strength was differentially associated with episodic memory trajectories depending on APOE4 genotype.Our findings suggest differential effects of aging and AD pathology. Hypoconnectivity within PMC was related to aging and cognitive decline. MTL-PMC hyperconnectivity was related to early AD pathology and cognitive decline in APOE4 carriers. Future studies should investigate more diverse samples, nonetheless, our approach allowed us to identify longitudinal functional changes related to aging and early AD pathology, enhancing cross-sectional research. Hyperconnectivity has been proposed as a mechanism related to early AD pathology before, we now contribute specific functional connections to focus on in future research.
000278069 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000278069 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000278069 650_7 $$2Other$$aAPOE
000278069 650_7 $$2Other$$aAging
000278069 650_7 $$2Other$$aAlzheimer’s disease
000278069 650_7 $$2Other$$aEpisodic memory
000278069 650_7 $$2Other$$aFMRI
000278069 650_7 $$2Other$$aFunctional connectivity
000278069 650_7 $$2NLM Chemicals$$aApolipoprotein E4
000278069 650_7 $$2NLM Chemicals$$atau Proteins
000278069 650_2 $$2MeSH$$aHumans
000278069 650_2 $$2MeSH$$aMemory, Episodic
000278069 650_2 $$2MeSH$$aMale
000278069 650_2 $$2MeSH$$aFemale
000278069 650_2 $$2MeSH$$aAged
000278069 650_2 $$2MeSH$$aAlzheimer Disease: pathology
000278069 650_2 $$2MeSH$$aAlzheimer Disease: diagnostic imaging
000278069 650_2 $$2MeSH$$aAlzheimer Disease: genetics
000278069 650_2 $$2MeSH$$aAlzheimer Disease: physiopathology
000278069 650_2 $$2MeSH$$aAlzheimer Disease: psychology
000278069 650_2 $$2MeSH$$aAging: pathology
000278069 650_2 $$2MeSH$$aAging: psychology
000278069 650_2 $$2MeSH$$aApolipoprotein E4: genetics
000278069 650_2 $$2MeSH$$aLongitudinal Studies
000278069 650_2 $$2MeSH$$aPositron-Emission Tomography
000278069 650_2 $$2MeSH$$aBrain: diagnostic imaging
000278069 650_2 $$2MeSH$$aBrain: pathology
000278069 650_2 $$2MeSH$$aBrain: physiopathology
000278069 650_2 $$2MeSH$$aMagnetic Resonance Imaging
000278069 650_2 $$2MeSH$$aAged, 80 and over
000278069 650_2 $$2MeSH$$aMiddle Aged
000278069 650_2 $$2MeSH$$aNeural Pathways: physiopathology
000278069 650_2 $$2MeSH$$aNeural Pathways: diagnostic imaging
000278069 650_2 $$2MeSH$$atau Proteins: cerebrospinal fluid
000278069 7001_ $$00000-0002-6702-3851$$aAdams, Jenna N$$b1
000278069 7001_ $$0P:(DE-2719)9002180$$aMolloy, Eóin N.$$b2
000278069 7001_ $$0P:(DE-2719)9000804$$aVockert, Niklas$$b3
000278069 7001_ $$aTremblay-Mercier, Jennifer$$b4
000278069 7001_ $$aRemz, Jordana$$b5
000278069 7001_ $$00000-0001-5218-3337$$aPichet Binette, Alexa$$b6
000278069 7001_ $$00000-0003-2338-0467$$aVilleneuve, Sylvia$$b7
000278069 7001_ $$0P:(DE-2719)2811815$$aMaass, Anne$$b8$$eLast author
000278069 7001_ $$aGroup, PREVENT-AD Research$$b9$$eCollaboration Author
000278069 773__ $$0PERI:(DE-600)2506521-X$$a10.1186/s13195-025-01742-6$$gVol. 17, no. 1, p. 91$$n1$$p91$$tAlzheimer's research & therapy$$v17$$x1758-9193$$y2025
000278069 8564_ $$uhttps://pub.dzne.de/record/278069/files/DZNE-2025-00560.pdf$$yOpenAccess
000278069 8564_ $$uhttps://pub.dzne.de/record/278069/files/DZNE-2025-00560.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000278069 909CO $$ooai:pub.dzne.de:278069$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000278069 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002356$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000278069 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002180$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000278069 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000804$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000278069 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811815$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000278069 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000278069 9141_ $$y2025
000278069 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-13
000278069 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-13
000278069 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000278069 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-13
000278069 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZHEIMERS RES THER : 2022$$d2024-12-13
000278069 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-04-10T15:32:54Z
000278069 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-04-10T15:32:54Z
000278069 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-13
000278069 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-13
000278069 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-13
000278069 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000278069 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-13
000278069 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-13
000278069 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bALZHEIMERS RES THER : 2022$$d2024-12-13
000278069 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-13
000278069 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-13
000278069 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-13
000278069 9201_ $$0I:(DE-2719)1311001$$kAG Maaß$$lMultimodal Neuroimaging$$x0
000278069 980__ $$ajournal
000278069 980__ $$aVDB
000278069 980__ $$aUNRESTRICTED
000278069 980__ $$aI:(DE-2719)1311001
000278069 9801_ $$aFullTexts